{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/VRCA/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-14T23:56:45.154Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":4092,"canonical_name":"Verrica Pharmaceuticals Inc.","cik":"0001660334","uei":null,"lei":null,"duns":null,"ticker":"VRCA"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"clinical":2,"sec":10},"count":12,"timeline":[{"ts":"2026-09-03","kind":"clinical.trial","reporter":"Verrica Pharmaceuticals Inc.","title":"Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07637734","excerpt":"[\"Common Warts\",\"Common Warts (Verruca Vulgaris)\",\"Human Papilloma Virus (HPV)\",\"Warts\"]","importance":60},{"ts":"2026-08-18","kind":"sec.filing","form_type":"4","title":"4 — Verrica Pharmaceuticals Inc. — 2026-08-18","url_slug":"/sec/cik-0001660334/4/0002043558-26-000005","accession_number":"0002043558-26-000005","importance":30},{"ts":"2026-08-18","kind":"sec.filing","form_type":"4","title":"4 — Verrica Pharmaceuticals Inc. — 2026-08-18","url_slug":"/sec/cik-0001660334/4/0002046750-26-000004","accession_number":"0002046750-26-000004","importance":30},{"ts":"2026-08-06","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Verrica Pharmaceuticals Inc. — 2026-08-06","url_slug":"/sec/cik-0001660334/10-q/0001660334-26-000025","accession_number":"0001660334-26-000025","importance":45},{"ts":"2026-08-06","kind":"sec.filing","form_type":"8-K","title":"8-K — Verrica Pharmaceuticals Inc. — 2026-08-06","url_slug":"/sec/cik-0001660334/8-k/0001193125-26-338273","accession_number":"0001193125-26-338273","importance":35},{"ts":"2026-06-09","kind":"sec.filing","form_type":"8-K","title":"8-K — Verrica Pharmaceuticals Inc. — 2026-06-09","url_slug":"/sec/cik-0001660334/8-k/0001193125-26-263722","accession_number":"0001193125-26-263722","importance":35},{"ts":"2026-06-09","kind":"sec.filing","form_type":"4","title":"4 — Verrica Pharmaceuticals Inc. — 2026-06-09","url_slug":"/sec/cik-0001660334/4/0001745995-26-000002","accession_number":"0001745995-26-000002","importance":30},{"ts":"2026-06-09","kind":"sec.filing","form_type":"4","title":"4 — Verrica Pharmaceuticals Inc. — 2026-06-09","url_slug":"/sec/cik-0001660334/4/0001814338-26-000002","accession_number":"0001814338-26-000002","importance":30},{"ts":"2026-06-09","kind":"sec.filing","form_type":"4","title":"4 — Verrica Pharmaceuticals Inc. — 2026-06-09","url_slug":"/sec/cik-0001660334/4/0001814892-26-000002","accession_number":"0001814892-26-000002","importance":30},{"ts":"2026-06-09","kind":"sec.filing","form_type":"4","title":"4 — Verrica Pharmaceuticals Inc. — 2026-06-09","url_slug":"/sec/cik-0001660334/4/0002043558-26-000002","accession_number":"0002043558-26-000002","importance":30},{"ts":"2026-06-09","kind":"sec.filing","form_type":"4","title":"4 — Verrica Pharmaceuticals Inc. — 2026-06-09","url_slug":"/sec/cik-0001660334/4/0002046750-26-000002","accession_number":"0002046750-26-000002","importance":30},{"ts":"2026-05-05","kind":"clinical.trial","reporter":"Verrica Pharmaceuticals Inc.","title":"Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07457918","excerpt":"[\"Common Warts (Verruca Vulgaris)\",\"Common Warts\",\"Human Papilloma Virus (HPV)\",\"Warts\"]","importance":60}]}